# Eversight – FDA Inspection, Feb 19, 2019

Source: https://www.keypedia.com/records/fda_inspections/eversight/f5b96dfd-2077-4230-ba3f-e2e08e875fe4
Source feed: FDA_Inspections

> FDA inspection 1079760 of Eversight, February 19, 2019. Classification: No Action Indicated (NAI). 2 citations under 21 CFR part 1271. Form 483 issued. 6 other FDA inspections on record for this company.

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 1079760
- Company Name: Eversight
- Inspection Date: 2019-02-19
- Classification: No Action Indicated (NAI)
- Classification Code: NAI
- Project Area: Blood and Blood Products
- Product Type: Biologics
- Center: Biologics
- Office Name: Center for Biologics Evaluation and Research
- Citation Count: 2

## Related Documents

- FDA Inspection 1178408 - 2022-08-18
- FDA Inspection 986660 - 2016-09-22
- [FDA Inspection 872698 - 2014-04-02](https://www.keypedia.com/records/fda_inspections/eversight/606871a9-62d2-44df-974a-460cf8896b1e)
- FDA Inspection 793821 - 2012-08-09
- FDA Inspection 632949 - 2009-12-04

## Related Officers

- [Company Rep](https://www.keypedia.com/people/jennifer-l-custodio/489a8b9c-ab8d-4d37-b89c-6086889e825c)

Company: https://www.keypedia.com/companies/eversight/3e2c7eb6-1612-4466-aafd-abe8c42da52c

Office: https://www.keypedia.com/offices/center-for-biologics-evaluation-and-research/dd9e8ea7-6f04-4ed1-b0d7-e7e6b264570d